Literature DB >> 187321

Inhibition of tumor cell growth in vitro and in vivo by 1-beta-D-arabinofuranosylcytosine entrapped within phospholipid vesicles.

E Mayhew, D Papahadjopoulos, Y M Rustum, C Dave.   

Abstract

Phospholipid vesicles have been used as a carrier vehicle to enhance the cytotoxic activity of 1-beta-D-arabinofuranosyl-cytosine (ara-C) and 1-beta-D-arabinofuranosylcytosine 5'-triphosphate against several tumor cell lines. The activity of both compounds in free solution or entrapped within phospholipid vesicles was compared against L1210 cells, Ehrlich ascites cells, and SV40-transformed 3T3 cells in vitro. In addition, the activity of vesicle-entrapped ara-C against L1210 cells was also studied in vivo. The results obtained in vitro with ara-C indicated no difference in the concentration needed to inhibit growth of cells by 50% between free ara-C and vesicle-entrapped ara-C. In contrast, 1-beta-D-arabinofuranosylcytosine 5'-triphosphate entrapped in phospholipid vesicles was a more potent inhibitor of L1210 in culture (ID50, 2 X 10(-8) M) compared to the relatively inactive free 1-beta-D-arabinofuranosylcytosine 5'-triphosphate (id50 greater than 10(-7) M). Experiments carried out with L1210 cells in mice showed that, after a single i.p. dose (10 mg/kg) of vesicle-entrapped ara-C, the average survival times of mice inoculated with 10(5) L1210 cells were increased by over 90%. In control experiments, free ara-C or vesicles plus free ara-C (10 mg/kg) did not prolong survival of mice.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 187321

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Liposomes as vehicles for cellular incorporation of biologically active macromolecules.

Authors:  D Paphadjopoulos; T Wilson; R Taber
Journal:  In Vitro       Date:  1980-01

Review 2.  Potential of liposomes as drug-carriers in cancer chemotherapy: a review.

Authors:  S B Kaye; V J Richardson
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

3.  Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation.

Authors:  F Szoka; D Papahadjopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  1978-09       Impact factor: 11.205

Review 4.  From stealthy polymersomes and filomicelles to "self" Peptide-nanoparticles for cancer therapy.

Authors:  Núria Sancho Oltra; Praful Nair; Dennis E Discher
Journal:  Annu Rev Chem Biomol Eng       Date:  2014       Impact factor: 11.059

5.  Clinical pharmacology of N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in patients with hematologic malignancies.

Authors:  T Ueda; T Nakamura; D Kagawa; M Uchida; N Domae; M Sugiyama; Y Ueda; M Sasada; H Uchino
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  Increased therapeutic efficiency of a lipid-soluble alkylating agent incorporated in liposomes.

Authors:  J W Babbage; M C Berenbaum
Journal:  Br J Cancer       Date:  1982-06       Impact factor: 7.640

7.  Effect of liposomally trapped antitumour drugs on a drug-resistant mouse lymphoma in vivo.

Authors:  V J Richardson; B E Ryman
Journal:  Br J Cancer       Date:  1982-04       Impact factor: 7.640

8.  Enhancement of both intracellular uptake and antitumor action of cisplatinum on human neuroblastoma cells by encapsulation in liposomes.

Authors:  Y Kamio; H Kato; T Kishikawa; T Toda; S Sasaki; J Ito; T Kato; R Tanaka
Journal:  Jpn J Cancer Res       Date:  1989-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.